triple negative breast cancer Archives -

For the first time, patients in England with triple-negative breast cancer (TNBC) will be able to access immunotherapy

NICE backs use of MSD’s KEYTRUDA for triple-negative breast cancer

https://pharmaphorum.com/news/nice-backs-use-of-msds-keytruda-for-triple-negative-breast-cancer/

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Scotland backs three new uses for MSD’s Keytruda

Phil Taylor Eisai, endometrial cancer, HEOR, Keytruda, Lenvima, Merck & Co, renal cell carcinoma, Scottish Medicines Consortium, triple negative breast cancer 0 Comment

Scotland has become the first country in the UK to back NHS funding for the use of Merck

Scotland backs three new uses for MSD’s Keytruda

https://pharmaphorum.com/news/scotland-backs-three-new-uses-for-msds-keytruda/

Market Access/ News/ News/ News/ Oncology

NICE finds solution to making Keytruda available for TNBC

Phil Taylor HEOR, Keytruda, market access, Merck & Co, NICE, Roche, Tecentriq, triple negative breast cancer 0 Comment

Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other

NICE finds solution to making Keytruda available for TNBC

https://pharmaphorum.com/news/nice-finds-solution-to-making-keytruda-available-for-tnbc/

Market Access/ News/ News

NICE says no to Keytruda in triple-negative breast cancer

Phil Taylor HEOR, immuno-oncology, Keytruda, Merck & Co, NHS, NICE, Oncology, triple negative breast cancer 0 Comment

There isn’t enough evidence to support the use of Merck & Co/MSD’s Keytruda in combination with chemotherapy as

NICE says no to Keytruda in triple-negative breast cancer

https://pharmaphorum.com/news/nice-says-no-to-keytruda-in-triple-negative-breast-cancer/

News/ News/ Oncology

AZ, Daiichi take aim at Gilead in triple-negative breast cancer

Phil Taylor antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, datopotamab deruxtecan, Gilead Sciences, Oncology, triple negative breast cancer, Trodelvy 0 Comment

AstraZeneca and Daiichi Sankyo have reported new data with their antibody-drug conjugate for triple-negative breast cancer (TNBC), as

AZ, Daiichi take aim at Gilead in triple-negative breast cancer

https://pharmaphorum.com/news/az-daiichi-take-aim-at-gilead-in-triple-negative-breast-cancer/

News/ News/ Oncology

Gilead moves closer to Chinese filing for Trodelvy in TNBC

Phil Taylor China, Everest Medicines, Gilead Sciences, Oncology, triple negative breast cancer, Trodelvy 0 Comment

Gilead Sciences’ Trodelvy has met its objectives in a phase 2b trial in triple-negative breast cancer (TNBC) carried

Gilead moves closer to Chinese filing for Trodelvy in TNBC

https://pharmaphorum.com/news/gilead-moves-closer-to-chinese-filing-for-trodelvy-in-tnbc/

News/ News/ Oncology

Gilead tags Merck for first-line triple negative breast cancer trial

Phil Taylor Gilead Sciences, immuno-oncology, Keytruda, Merck & Co, Oncology, triple negative breast cancer, Trodelvy 0 Comment

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get?

Gilead tags Merck for first-line triple negative breast cancer trial

https://pharmaphorum.com/news/gilead-tags-merck-for-first-line-triple-negative-breast-cancer-trial/

News/ News/ Oncology

Merck gets EU approval for Keytruda in triple-negative breast cancer

Phil Taylor immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, Roche, Tecentriq, triple negative breast cancer 0 Comment

Merck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form

Merck gets EU approval for Keytruda in triple-negative breast cancer

https://pharmaphorum.com/news/merck-gets-eu-approval-for-keytruda-in-triple-negative-breast-cancer/

News/ News/ Oncology

After false start, Merck claims Keytruda approval in early breast cancer

Phil Taylor fda, immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, triple negative breast cancer 0 Comment

Merck & Co’s Keytruda has just picked up its 30th approval from the FDA, and it is a

After false start, Merck claims Keytruda approval in early breast cancer

https://pharmaphorum.com/news/after-false-start-merck-claims-keytruda-approval-in-early-breast-cancer/

Trending

triple negative breast cancer

Login